Why the study?
Does the curcumin analog C66 prevent high glucose-induced inflammation and diabetic cardiomyopathy in preclinical models?
Does the curcumin analog C66 prevent high glucose-induced inflammation and diabetic cardiomyopathy in preclinical models?
The novel curcumin analog C66 protects against diabetic cardiomyopathy by inhibiting JNK phosphorylation, reducing inflammation and apoptosis.
Answers are grounded in this paper and cite their sources.
Supports JNK inhibition as a target in diabetic cardiomyopathy models; leaves open translation to human therapy.
Hyperglycemia-induced inflammation and apoptosis have important roles in the pathogenesis of diabetic cardiomyopathy. We recently found that a novel curcumin derivative, C66, is able to reduce the high glucose (HG)-induced inflammatory response. This study was designed to investigate the protective effects on diabetic cardiomyopathy and its underlying mechanisms. Pretreatment with C66 significantly reduced HG-induced overexpression of inflammatory cytokines via inactivation of nuclear factor-κB in both H9c2 cells and neonatal cardiomyocytes. Furthermore, we showed that the inhibition of Jun NH2-terminal kinase (JNK) phosphorylation contributed to the protection of C66 from inflammation and cell apoptosis, which was validated by the use of SP600125 and dominant-negative JNK. The molecular docking and kinase activity assay confirmed direct binding of C66 to and inhibition of JNK. In mice with type 1 diabetes, the administration of C66 or SP600125 at 5 mg/kg significantly decreased the levels of plasma and cardiac tumor necrosis factor-α, accompanied by decreasing cardiac apoptosis, and, finally, improved histological abnormalities, fibrosis, and cardiac dysfunction without affecting hyperglycemia. Thus, this work demonstrated the therapeutic potential of the JNK-targeting compound C66 for the treatment of diabetic cardiomyopathy. Importantly, we indicated a critical role of JNK in diabetic heart injury, and suggested that JNK inhibition may be a feasible strategy for treating diabetic cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Pan et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: